MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemiaAthalia R. Pyzer, David Avigan, Mary Paty Bryant et al.|Blood|2017Cited by 193
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host diseaseMyrna Nahas, Jacalyn Rosenblatt, Robert J. Soiffer et al.|Blood|2018Cited by 48
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 TrialCiara Louise Freeman, Matthew J. Frigault, Binod Dhakal et al.|Blood|2024Cited by 20
Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid LeukemiaJessica Liegel, David Avigan, Jacalyn Rosenblatt et al.|Blood|2017Cited by 4
Development of Novel Second Generation DC/Tumor Fusion Vaccine in LymphomaShira Orr, David Avigan, Marzia Capelletti et al.|Blood|2019Cited by 3